Results 241 to 250 of about 709,386 (365)
Screening of 250 natural products identified ginsenoside Rb1 (gRb1) as a potent modulator of regulatory T cells (Tregs) and inflammatory T cells. gRb1 increased IL‐10‐ and TGF‐β‐expressing Tregs while reducing Th17, Th1, and Th2 populations in both asthma model mice and human PBMCs.
Susanna Choi+14 more
wiley +1 more source
The Place of Appendicectomy in Inflammatory Bowel Disease—A Review
ABSTRACT The aetiology and pathophysiology of inflammatory bowel disease (IBD) are not completely understood; however, a dysregulated intestinal immune system appears key to its pathogenesis. It has been suggested that the appendix is central to nurturing the enteric mucosal system due to its production of lymphoid products and that an appendicectomy ...
Krishanth Naidu+4 more
wiley +1 more source
Th17 and Treg Cells, Two New Lymphocyte Subpopulations with a Key Role in the Immune Response Against Infection [PDF]
Rolando Vernal, José A. García‐Sanz
openalex +1 more source
During the pathological process of immune thrombocytopenia, signal transducer and activator of transcription 3 (STAT3) is activated by JAKs, leading to the production of a large number of inflammatory cytokines and promoting the activation of Th1, Th2 and Th17 cells.
Yingbin Yue+4 more
wiley +1 more source
Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6 [PDF]
Wenda Gao+6 more
openalex +1 more source
Graphical representation of the widespread white matter (blue color mask) and grey matter (cortical and deep grey matter; red color mask) demyelination in MS cases characterized by substantial inflammation of the CP (A). The presence of lesions was mainly associated with periventricular white matter and hippocampus areas (A).
R. Magliozzi+19 more
wiley +1 more source
Estrogen Receptor α Signaling in T Lymphocytes Is Required for Estradiol-Mediated Inhibition of Th1 and Th17 Cell Differentiation and Protection against Experimental Autoimmune Encephalomyelitis [PDF]
Karine Lélu+8 more
openalex +1 more source
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley +1 more source